Case Report of a Local Recurrence of Spindle Cell Embryonal Rhabdomyosarcoma

Francesk Mulita, Nikolaos Parchas, Stylianos Germanos, Spyros Papadoulas, Ioannis Maroulis

ABSTRACT
Introduction: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and adolescents. Spindle cell RMS is a rare variant of embryonal RMS that has a predilection for young males. Aim: We are presenting here a case of a local recurrence of an embryonal variant of the spindle cell RMS in a 19-year-old male. Case report: In this report it is described the study of patient with local recurrence of spindle cell embryonal RMS of the left testis after left orchiectomy and adjuvant chemotherapy. Computed tomography of the abdomen was used to evaluate the tumor. The recurrent mass was about 7.5cm and the patient was operated and discharged after 6 days in a good condition. Six months after the operation the patient had a new recurrence of RMS in the left retroperitoneal space. Conclusion: RMS is a malignant tumor of mesenchymal origin that is treated by a combination of surgery, chemotherapy, and radiation. However, up to one-third of patients experience recurrence. Keywords: Rhabdomyosarcoma, embryonal, spindle, recurrence.

1. INTRODUCTION
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and adolescents, accounting for approximately 5% of all pediatric cancers and about one-half of all soft tissue sarcomas. It is the third most common extracranial solid tumor in children (1). Rhabdomyosarcoma types include embryonal rhabdomyosarcoma (approximately 60%), alveolar (approximately 20%), pleomorphic (approximately 10%), and spindle (approximately 10%) (2-4). Spindle cell RMS is a rare variant of embryonal RMS that is associated with a favorable outcome, in comparison with other subtypes. However, in the adult population, there does not appear to be any prognostic advantage (5).

2. AIM
The aim of this article is to present reports of a case of a local recurrence of an embryonal variant of the spindle cell RMS in a 19-year-old male.

3. CASE REPORT
A 19-year-old male underwent a total left orchiectomy 2 years ago with a diagnosis of a spindle cell variant of embryonal rhabdomyosarcoma of the left testis. He received adjuvant chemotherapy. The patient had a repeat abdominal Computed Tomography (CT) scan 2 years after the operation, without having any other sign or symptom until then. The CT scan revealed a retroperitoneal mass measured 6.75cm x 5.27cm x 7.46cm in diameter, coming from the left spermatic cord (Figure 1 and 2). The surgery was made in the General University Hospital of Patras by a team of general and vascular surgeons. In the operation the tumor was found to be next to the left external iliac artery. It was decided to cut the left external iliac artery (Figure 3) and an anastomosis was made between left femoral artery and the left external iliac artery with a synthetic polytetrafluoroethylene (PTFE) graft (Gore-Tex 8mm x 50 mm) (Figure 4). The patient had no postoperative complication during his hospitalization and was discharged 6 days after the surgery in a good condition. Six months after the operation the patient had a new recurrence of RMS in the left retroperitoneal space.
4. DISCUSSION
The spindle cell variant of embryonal rhabdomyosarcoma was first recognized as a rare entity having a male predilection, propensity for occurrence in the paratesticular, and head and neck regions, and a low malignant potential, in 1992 by German-Italian Cooperative Soft Tissue Sarcoma Study. It accounts for 3-4.4 % of all subtypes of rhabdomyosarcoma (6-7). The tumours usually present as a gradually increasing painless, firm swelling (8-9). Even though embryonal RMS is common, the spindle cell variant is considered rare. RMS is treated by a combination of surgery, chemotherapy, and radiation. If the tumor is surgically inoperable, then initially radiotherapy and chemotherapy given to shrink a tumor followed by wide surgical excision of the tumor performed. Chemotherapeutic agents commonly used are vincristine, cyclophosphamide, dactinomycin, adriamycin, ifosfamide, and etoposide (5). The surgical management of patients with RMS is site-specific, and attempts for complete tumor resection should be made. Complete tumor resection is generally not advised if there is a significant risk for functional or cosmetic morbidity (for example, in head and neck RMS). Complete compartmental resection is not required for tumors arising within a muscle, as long as a minimum of 0.5 cm of margins is obtained (10). Although the majority of children with non-metastatic RMS now achieve complete tumor remission with current multidisciplinary treatment, which includes chemotherapy, radiotherapy and surgery, up to one-third of patients experience recurrence (11-13). Survival after recurrence is poor, and new salvage therapy strategies are needed (14-15).

5. CONCLUSION
The spindle cell variant is considered to be a rare type of rhabdomyosarcoma, that is treated by a combination of surgery, chemotherapy, and radiation. It is associated with a favorable outcome, in comparison with other subtypes. However, in the adult population, there does not appear to be any prognostic advantage. In addition, survival after recurrence is poor.

• Author’s contribution: All authors were included in all steps of preparation this case study. Final proof reading was made by the first author.
• Declaration of conflicting interests: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
• Financial support and sponsorship: The authors received no financial support for the research, authorship, and/or publication of this article.

REFERENCES
1. Dasgupta R, Rodeberg DA. Update on rhabdomyosarcoma. Semin Pediatr Surg. 2012; 21(1): 68-78.
2. Dagher R, Helman L. Rhabdomyosarcoma: an overview. Oncologist. 1999;4(1):34-44.
3. Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, et al. Germline Mutations in Predisposition Genes in Pediatric Cancer. N Engl J Med. 2015 Dec 10; 373(24): 2336-2346.
4. Kaseb H, Kuhn J, Babiker HM. Cancer, Rhabdomyosarcoma. [Updated 2019 Nov 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507721/
5. Singh AP, Gupta AK, Jindal A, Mangal K. Retroperitoneal spindle cell variant of embryonal rhabdomyosarcoma in a child. Med J DY Patil Vidyapeeth. 2019; 12: 177-179.
6. Cavazzana AO, Schmidt D, Nino V, et al. Spindle cell rhabdomyosarcoma. A prognostically favorable variant of rhabdomyosarcoma. Am J Surg Pathol. 1992; 16(3): 229-235.
7. Weiss SS, Goldblum JR. Enzinger and Weiss's Soft Tissue
Case Report of a Local Recurrence of Spindle Cell Embryonal Rhabdomyosarcoma

Tumours. 5th ed. Philadelphia: Elsevier; 2008. Rhabdomyosarcoma. In: Weiss SS, Goldblum JR eds; pp. 595–632. [Google Scholar]

8. Carroll SJ, Nodit L. Spindle Cell rhabdomyosarcoma. A brief diagnostic review and differential diagnosis. Arch Pathol Lab Med. 2013;137:1155–58. [PubMed] [Google Scholar]

9. Kaur P, Kaur A, Suri AK, Malik H. Spindle Cell Variant of Embryonal Rhabdomyosarcoma: A Rare Entity with Diagnostic Challenges. J Clin Diagn Res. 2016;10(8):ED17–ED18. doi:10.7860/JCDR/2016/19785.8359

10. Leaphart C, Rodeberg D. Pediatric surgical oncology: management of rhabdomyosarcoma. Surg Oncol. 2007;16(3):173–185. [PubMed] [Google Scholar]

11. Stevens MCG, Rey A, Bouvet N, et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence. Results of the third study of the International Society of Paediatric Oncology—SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol. 2005;23:2618 –2628

12. Koscielniak E, Harms D, Henze G, et al. Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol. 1999;17:3706 –3719

13. Crist WM, Anderson JR, Meza JL, et al. Intergroup Rhabdomyosarcoma Study-IV: results for patients with nonmetastatic disease. J Clin Oncol. 2001;19:3091–3102

14. Pappo AS, Anderson JR, Crist WM, et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol. 1999;17:3487–3493.

15. Mazzoleni, S., Bisogno, G., Garaventa, A., Cecchetto, G., Ferrari, A. et al., (2005). Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma. Cancer, 104(1), 183–190. doi:10.1002/cncr.21138